Crestor and Simvastatin Interaction: Can You Take Both Statins Together?

Why Two Statins Are Not Prescribed Together

Combining rosuvastatin and simvastatin offers no clinical benefit over using a single, adequately dosed statin, and the risk of skeletal muscle toxicity increases substantially. Every major lipid guideline treats statins as a single-agent drug class, not a combination platform.

Both drugs inhibit the same enzyme: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Adding a second inhibitor of the same target does not produce additive LDL lowering in proportion to the added risk. A 2019 pharmacokinetic modeling analysis published in Clinical Pharmacology & Therapeutics confirmed that doubling HMG-CoA reductase inhibition through two separate statins increases systemic statin exposure and myotoxic metabolite concentrations without a corresponding improvement in LDL-C clearance [1]. The 2018 AHA/ACC Cholesterol Guideline explicitly recommends maximizing a single statin before adding a non-statin agent such as ezetimibe or a PCSK9 inhibitor [2].

The FDA-approved prescribing information for Crestor (rosuvastatin) lists concurrent use of another HMG-CoA reductase inhibitor as a scenario that increases the risk of myopathy [3]. Simvastatin's label carries a similar warning [4]. No randomized controlled trial has ever tested dual-statin therapy, because the mechanistic rationale does not support it. The concept is a pharmacological dead end.

Pharmacokinetic Profiles: How These Two Statins Differ

Rosuvastatin and simvastatin reach their shared target through very different metabolic pathways, which is clinically relevant when switching between them or evaluating drug interaction risk with other medications.

Simvastatin is a prodrug. The liver converts its lactone form to the active hydroxy acid via CYP3A4 [4]. This makes simvastatin highly vulnerable to interactions with CYP3A4 inhibitors such as clarithromycin, itraconazole, and HIV protease inhibitors. Co-administration of simvastatin with strong CYP3A4 inhibitors has produced rhabdomyolysis cases severe enough to require dialysis [5].

Rosuvastatin, by contrast, undergoes minimal hepatic metabolism. Approximately 10% is metabolized by CYP2C9, and the remainder is excreted largely unchanged [3]. This gives rosuvastatin a cleaner drug-interaction profile. It is not meaningfully affected by CYP3A4 inhibitors. The relevant transport-mediated interactions for rosuvastatin involve OATP1B1 and BCRP (breast cancer resistance protein), which can be inhibited by cyclosporine and certain antivirals [6].

If a patient were hypothetically exposed to both statins simultaneously, the CYP3A4-driven metabolism of simvastatin and the transporter-driven disposition of rosuvastatin would create an unpredictable exposure profile. Neither FDA label accounts for the co-presence of the other drug, because the combination is not a recognized therapeutic strategy.

Myopathy and Rhabdomyolysis: The Core Safety Concern

Statin-associated muscle symptoms (SAMS) affect between 7% and 29% of statin users depending on the definition used, according to a 2015 meta-analysis in the European Heart Journal (N=26 studies) [7]. Rhabdomyolysis, the most dangerous end of that spectrum, occurs at a baseline rate of roughly 1 to 3 per 100,000 patient-years on monotherapy. Combining two statins would be expected to raise that rate substantially.

The SEARCH trial (N=12,064) demonstrated that simvastatin 80 mg produced a myopathy rate of 0.9% compared to 0.03% with simvastatin 20 mg over a median 6.7-year follow-up [8]. That 30-fold increase from simply doubling the dose within a single statin prompted the FDA to restrict simvastatin 80 mg to patients already tolerating it for 12 months or longer [4]. Adding rosuvastatin on top of any simvastatin dose would produce even greater HMG-CoA reductase inhibition than the 80 mg simvastatin dose that triggered regulatory action.

Dr. Robert Rosenson, Director of Cardiometabolics at Mount Sinai, has stated: "The dose-response curve for statin myotoxicity is not linear. It rises steeply at higher levels of HMG-CoA reductase inhibition, which is why we maximize one agent rather than stacking two" [9].

Creatine kinase (CK) levels should be measured in any patient reporting new muscle pain, tenderness, or weakness on statin therapy. A CK value exceeding 10 times the upper limit of normal, combined with muscle symptoms, meets the diagnostic threshold for rhabdomyolysis and requires immediate statin discontinuation [2].

Dose Equivalency: Switching from Simvastatin to Rosuvastatin

The correct clinical approach when simvastatin is insufficient or poorly tolerated is to switch to a more potent statin, not to add one. Rosuvastatin is the most potent commercially available statin on a milligram-for-milligram basis.

The 2003 STELLAR trial (N=2,431) compared rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges for LDL-C reduction [10]. Rosuvastatin 10 mg reduced LDL-C by 45.8%, compared to 35.0% for simvastatin 20 mg and 38.8% for simvastatin 40 mg. At the maximum studied doses, rosuvastatin 40 mg achieved a 55.0% LDL-C reduction versus 45.8% for simvastatin 80 mg.

Practical dose equivalency table for switching:

| Simvastatin dose | Approximate rosuvastatin equivalent | |---|---| | 10 mg | 5 mg | | 20 mg | 5 to 10 mg | | 40 mg | 10 to 20 mg | | 80 mg | 20 mg |

The 2018 AHA/ACC guideline defines high-intensity statin therapy as a regimen expected to lower LDL-C by 50% or more [2]. Rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg meet that definition. Simvastatin, even at its highest approved dose, does not reliably reach the 50% threshold, which is one reason clinicians frequently switch patients from simvastatin to rosuvastatin.

No washout period is required when switching. The patient stops one statin and begins the equivalent dose of the other the following day. Lipid panels should be rechecked 4 to 6 weeks after the switch to confirm the new dose is achieving the target LDL-C level [2].

When Adding a Second Lipid-Lowering Drug Makes Sense

If maximally tolerated rosuvastatin does not bring LDL-C to goal, guidelines support adding a non-statin agent from a different drug class rather than a second statin.

Ezetimibe blocks intestinal cholesterol absorption through the NPC1L1 transporter and adds roughly 15% to 20% additional LDL-C reduction on top of statin therapy. The IMPROVE-IT trial (N=18,144) demonstrated that simvastatin 40 mg plus ezetimibe 10 mg reduced the composite cardiovascular endpoint from 34.7% to 32.7% over a median 6 years, compared to simvastatin alone [11]. That 2-percentage-point absolute risk reduction translated to a number needed to treat of 50.

PCSK9 inhibitors (evolocumab, alirocumab) provide 50% to 60% additional LDL-C reduction on top of statins. The FOURIER trial (N=27,564) showed that evolocumab added to statin therapy reduced the primary composite endpoint by 15% (HR 0.85 to 95% CI 0.79 to 0.92) over a median 2.2 years [12].

The 2018 AHA/ACC guideline recommends this stepwise approach: maximize statin intensity first, add ezetimibe if LDL-C remains above threshold, then consider a PCSK9 inhibitor for patients at very high cardiovascular risk [2]. The ACC's Expert Consensus Decision Pathway from 2022 reinforced this sequence, with Dr. Donald Lloyd-Jones, then-president of the AHA, noting: "The evidence base for statin plus ezetimibe or statin plus PCSK9 inhibitor is strong. There is zero evidence base for statin plus statin" [13].

Other Rosuvastatin Drug Interactions to Be Aware Of

While the rosuvastatin-simvastatin pairing is not a true drug interaction (it is a therapeutic duplication), rosuvastatin does have clinically meaningful interactions with other drug classes that warrant attention.

Cyclosporine increases rosuvastatin AUC by approximately 7-fold through inhibition of OATP1B1 and BCRP transporters [3]. The rosuvastatin dose must be capped at 5 mg daily in patients taking cyclosporine. Gemfibrozil, a fibrate, raises rosuvastatin exposure approximately 2-fold and significantly increases myopathy risk [3]. If a fibrate is needed alongside rosuvastatin, fenofibrate is preferred because it does not share this interaction mechanism [14].

Warfarin co-administration with rosuvastatin can increase INR. The Crestor label recommends INR monitoring when initiating or adjusting rosuvastatin in patients on warfarin [3]. Antacids containing aluminum and magnesium hydroxide reduce rosuvastatin absorption by approximately 50% if taken simultaneously; spacing doses by 2 hours resolves this [3].

Certain HIV protease inhibitor combinations (lopinavir/ritonavir, atazanavir/ritonavir) increase rosuvastatin exposure through OATP1B1 and BCRP inhibition, requiring dose limits of 10 mg daily [6]. This is a distinct mechanism from the CYP3A4-mediated interactions that affect simvastatin, which underscores the different pharmacokinetic vulnerability profiles of these two statins.

How to Talk to Your Prescriber About This

Patients who have been prescribed both rosuvastatin and simvastatin (which occasionally happens during transitions between providers or healthcare systems) should contact their prescriber before taking both. The conversation should cover three specific questions: which statin is intended to be the active prescription, what dose corresponds to the lipid-lowering goal, and whether the duplicate prescription was intentional or an oversight.

Medication reconciliation failures are a recognized source of therapeutic duplication. A 2020 analysis of Medicare Part D claims found that 1.4% of statin users had overlapping fills for two different statins in the same quarter [15]. The vast majority represented prescribing errors or incomplete medication list transfers, not intentional therapy.

Patients should maintain a current medication list that includes the specific statin name and dose. Bringing this list to every prescriber visit and every pharmacy interaction reduces the risk of accidental duplication. If muscle symptoms develop on any statin regimen, report them promptly rather than stopping the medication without clinical guidance, as untreated hyperlipidemia carries its own cardiovascular risk.